HR-NBL2 (Neuroblastoma)
Clinical study of the treatment of children and young adults with a newly diagnosed high-risk neuroblastoma
Recruiting
Who can enter
Children with a newly diagnosed high-risk neuroblastoma
0 till 21 years old
Goal
The goal of this study is to improve the treatment of children and young adults with newly diagnosed high-risk neuroblastoma.
Background
Currently, we cannot cure all patients with neuroblastoma. Therefore, we want to improve treatment. During different phases of the treatment, we investigate whether modification of the standard treatment ensures a better treatment outcome.
Some patients require additional treatment after induction chemotherapy. We aim to investigate whether administering chemotherapy together with immunotherapy leads to the disappearance of metastases.
After induction chemotherapy and, if possible, surgery, a course of high-dose chemotherapy follows. We call this 'consolidation'. Normally, we give one course of high-dose chemotherapy. There is evidence that an additional course of chemotherapy improves treatment outcome. We are investigating whether giving two courses ensures a better treatment outcome.
The tumor is also irradiated afterwards. Some patients have a tumor remnant after surgery. We study whether giving an extra dose of radiotherapy on this remnant causes the tumor to return less often.
We also collect blood, urine and tumor tissue at different times. We want to use this body material for research into neuroblastoma.
In order to participate in a study please refer to your/your child’s doctor.
For international patients: please feel welcome to contact our International Patients Office.
Last reviewed
May 19, 2026
Study details
- Study details
Official title
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)Cancer type
NeuroblastomaPhase
3Maximum number of patients
1100, of whom 70 are expected to participate in the NetherlandsStart date
March 3, 2021Status
OpenLocal principal investigator
Prof. dr. G.A.M. TytgatSponsor
Institut Gustave Roussy, ParisApproval
The study of this new treatment has been reviewed by an accredited medical research ethics committee. This committee has decided that it is justified to ask patients to participate in this study. More information can be found at: CCMO.Trial registry number
ClinicalTrials.gov: NCT04221035
The above information is intended as a brief summary only and may not reflect the most up-to-date information. For full details and the current status of a protocol, physicians can contact the Princess Máxima Center directly.